Targeting the tumour profile using broad spectrum chimaeric antigen receptor T-cells

Biochemical Society Transactions

Volumn 44, Issue 2, 2016, Pages 391-396

  Navai, Shoba A ^a,b,c   Ahmed, Nabil ^a,b,c  

^a CENTER FOR CELL AND GENE THERAPY   (United States)

^b Texas Children's Cancer and Hematology Centers   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Antigen escape; Bispecific; Chimaeric antigen receptor; Multispecific; Tandem chimaeric antigen receptor (TanCAR); Tumour heterogeneity

Indexed keywords

CHIMERIC ANTIGEN RECEPTOR; T LYMPHOCYTE RECEPTOR; LYMPHOCYTE ANTIGEN RECEPTOR; TUMOR MARKER;

CANCER GROWTH; CELL SUBPOPULATION; GENE EXPRESSION; HUMAN; IMMUNOCOMPETENT CELL; MALIGNANT NEOPLASM; NONHUMAN; PRIORITY JOURNAL; PROTEIN TARGETING; REVIEW; SOLID TUMOR; STROMA CELL; T LYMPHOCYTE; TUMOR MICROENVIRONMENT; IMMUNOLOGY; NEOPLASM;

BIOMARKERS, TUMOR; HUMANS; NEOPLASMS; RECEPTORS, ANTIGEN, T-CELL; TUMOR MICROENVIRONMENT;

EID: 85009863183     PISSN: 03005127     EISSN: 14708752     Source Type: Journal    
DOI: 10.1042/BST20150266     Document Type: Review

References (48)

1. Campbell, P.J., Yachida, S., Mudie, L.J., Stephens, P.J., Pleasance, E.D., Stebbings, L.A., Morsberger, L.A., Latimer, C., McLaren, S., Lin, M.-L. et al. (2010) The patterns and dynamics of genomic instability in metastatic pancreatic cancer. Nature 467, 1109-1113
2. Yachida, S., Jones, S., Bozic, I., Antal, T., Leary, R., Fu, B., Kamiyama, M., Hruban, R.H., Eshleman, J.R., Nowak, M.A. et al. (2010) Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 467, 1114-1117
3. Anderson, K., Lutz, C., van Delft, F.W., Bateman, C.M., Guo, Y., Colman, S.M., Kempski, H., Moorman, A.V., Titley, I., Swansbury, J. et al. (2011) Genetic variegation of clonal architecture and propagating cells in leukaemia. Nature 469, 356-361
4. Wu, X., Northcott, P.A., Dubuc, A., Dupuy, A.J., Shih, D.J.H., Witt, H., Croul, S., Bouffet, E., Fults, D.W., Eberhart, C.G. et al. (2012) Clonal selection drives genetic divergence of metastatic medulloblastoma. Nature 482, 529-533
5. Ding, L., Ellis, M.J., Li, S., Larson, D.E., Chen, K., Wallis, J.W., Harris, C.C., McLellan, M.D., Fulton, R.S., Fulton, L.L. et al. (2010) Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature 464, 999-1005
6. Polanska, U.M. and Orimo, A. (2013) Carcinoma-associated fibroblasts: non-neoplastic tumour-promoting mesenchymal cells. J. Cell. Physiol. 228, 1651-1657
7. Junttila, M.R. and de Sauvage, F.J. (2013) Influence of tumour micro-environment heterogeneity on therapeutic response. Nature 501, 346-354
8. Pardoll, D.M. (2012) The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 12, 252-264
9. Gabrilovich, D.I., Ostrand-Rosenberg, S. and Bronte, V. (2012) Coordinated regulation of myeloid cells by tumours. Nat. Rev. Immunol. 12, 253-268
10. Dudley, M.E., Wunderlich, J.R., Yang, J.C., Sherry, R.M., Topalian, S.L., Restifo, N.P., Royal, R.E., Kammula, U., White, D.E., Mavroukakis, S.A. et al. (2005) Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J. Clin. Oncol. 23, 2346-2357
11. Pule, M., Finney, H. and Lawson, A. (2003) Artificial T-cell receptors. Cytotherapy 5, 211-226
12. Sadelain, M., Brentjens, R. and Riviere, I. (2013) The basic principles of chimeric antigen receptor design. Cancer Discov. 3, 388-398
13. Brown, C.E., Starr, R., Aguilar, B., Shami, A.F., Martinez, C., D'Apuzzo, M., Barish, M.E., Forman, S.J. and Jensen, M.C. (2012) Stem-like tumor-initiating cells isolated from IL13Rα2 expressing gliomas are targeted and killed by IL13-zetakine-redirected T cells. Clin. Cancer Res. 18, 2199-2209
14. Eshhar, Z., Waks, T., Gross, G. and Schindler, D.G. (1993) Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc. Natl. Acad. Sci. U.S.A. 90, 720-724
15. Irving, B.A. and Weiss, A. (1991) The cytoplasmic domain of the T cell receptor zeta chain is sufficient to couple to receptor-associated signal transduction pathways. Cell 64, 891-901
16. Wange, R.L., Kong, A.N. and Samelson, L.E. (1992) A tyrosine-phosphorylated 70-kDa protein binds a photoaffinity analogue of ATP and associates with both the zeta chain and CD3 components of the activated T cell antigen receptor. J. Biol. Chem. 267, 11685-11688
17. Stein, P.H., Fraser, J.D. and Weiss, A. (1994) The cytoplasmic domain of CD28 is both necessary and sufficient for costimulation of interleukin-2 secretion and association with phosphatidylinositol 3′-kinase. Mol. Cell. Biol. 14, 3392-3402
18. Alvarez-Vallina, L. and Hawkins, R.E. (1996) Antigen-specific targeting of CD28-mediated T cell co-stimulation using chimeric single-chain antibody variable fragment-CD28 receptors. Eur. J. Immunol. 26, 2304-2309
19. Finney, H.M., Lawson, A.D., Bebbington, C.R. and Weir, A.N. (1998) Chimeric receptors providing both primary and costimulatory signaling in T cells from a single gene product. J. Immunol. 161, 2791-2797
20. Maher, J., Brentjens, R.J., Gunset, G., Riviere, I. and Sadelain, M. (2002) Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta/CD28 receptor. Nat. Biotechnol. 20, 70-75
21. Moeller, M., Haynes, N.M., Trapani, J.A., Teng, M.W.L., Jackson, J.T., Tanner, J.E., Cerutti, L., Jane, S.M., Kershaw, M.H., Smyth, M.J. et al. (2004) A functional role for CD28 costimulation in tumor recognition by single-chain receptor-modified T cells. Cancer Gene Ther. 11, 371-379
22. Loskog, A., Giandomenico, V., Rossig, C., Pule, M., dotti, G. and Brenner, M.K. (2006) Addition of the CD28 signaling domain to chimeric T-cell receptors enhances chimeric T-cell resistance to T regulatory cells. Leukemia 20, 1819-1828
23. Savoldo, B., Ramos, C.A., Liu, E., Mims, M.P., Keating, M.J., Carrum, G., Kamble, R.T., Bollard, C.M., Gee, A.P., Mei, Z. et al. (2011) CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. J. Clin. Invest. 121, 1822-1826
24. Stephan, M.T., Ponomarev, V., Brentjens, R.J., Chang, A.H., Dobrenkov, K.V., Heller, G. and Sadelain, M. (2007) T cell-encoded CD80 and 4-1BBL induce auto- and transcostimulation, resulting in potent tumor rejection. Nat. Med. 13, 1440-1449
25. Zhong, X.-S., Matsushita, M., Plotkin, J., Riviere, I. and Sadelain, M. (2010) Chimeric antigen receptors combining 4-1BB and CD28 signaling domains augment PI3kinase/AKT/Bcl-XL activation and CD8 + T cell-mediated tumor eradication. Mol. Ther. 18, 413-420
26. Imai, C., Mihara, K., Andreansky, M., Nicholson, I.C., Pui, C.-H., Geiger, T.L. and Campana, D. (2004) Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia. Leukemia 18, 676-684
27. Pulè, M.A., Straathof, K.C., Dotti, G., Heslop, H.E., Rooney, C.M. and Brenner, M.K. (2005) A chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T cells. Mol. Ther. 12, 933-941
28. Hombach, A.A. and Abken, H. (2011) Costimulation by chimeric antigen receptors revisited the T cell antitumor response benefits from combined CD28-OX40 signalling. Int. J. Cancer 129, 2935-2944
29. Fousek, K. and Ahmed, N. (2015) The evolution of T-cell therapies for solid malignancies. Clin. Cancer Res. 21, 3384-3392
30. Porter, D.L., Levine, B.L., Kalos, M., Bagg, A. and June, C.H. (2011) Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N. Engl. J. Med. 365, 725-733
31. Kalos, M., Levine, B.L., Porter, D.L., Katz, S., Grupp, S.A., Bagg, A. and June, C.H. (2011) T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci. Transl. Med. 3, 1-11
32. Kochenderfer, J.N., Dudley, M.E., Carpenter, R.O., Kassim, S.H., Rose, J.J., Telford, W.G., Hakim, F.T., Halverson, D.C., Fowler, D.H., Hardy, N.M. et al. (2013) Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation. Blood 122, 4129-4139
33. Brentjens, R.J., Davila, M.L., Riviere, I., Park, J., Wang, X., Cowell, L.G., Bartido, S., Stefanski, J., Taylor, C., Olszewska, M. et al. (2013) CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci. Transl. Med. 5, 1-9
34. Grupp, S.A., Kalos, M., Barrett, D., Aplenc, R., Porter, D.L., Rheingold, S.R., Teachey, D.T., Chew, A., Hauck, B., Wright, J.F. et al. (2013) Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N. Engl. J. Med. 368, 1509-1518
35. Maude,S.L.,Frey,N.,Shaw,P.A.,Aplenc,R.,Barrett,D.M.,Bunin,N.J., Chew, A., Gonzalez, V.E., Zheng, Z., Lacey, S.F. et al. (2014) Chimeric antigen receptor T cells for sustained remissions in leukemia. N. Engl. J. Med. 371, 1507-1517
36. Sotillo, E., Barrett, D.M., Black, K.L., Bagashev, A., Oldridge, D., Wu, G., Sussman, R., Lanauze, C., Ruella, M., Gazzara, M.R. et al. (2015) Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy. Cancer Discov. 5, 1-14
37. Topp, M.S., Gökbuget, N., Zugmaier, G., Degenhard, E., Goebeler, M.-E., Klinger, M., Neumann, S.A., Horst, H.A., Raff, T., Viardot, A. et al. (2012) Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL. Blood 120, 5185-5187
38. Topp, M.S., Gokbuget, N., Zugmaier, G., Klappers, P., Stelljes, M., Neumann, S., Viardot, A., Marks, R., Diedrich, H., Faul, C. et al. (2014) Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia. J. Clin. Oncol. 32, 4134-4140
39. Hegde, M., Corder, A., Chow, K.K.H., Mukherjee, M., Ashoori, A., Kew, Y., Zhang, Y.J., Baskin, D.S., Merchant, F.A., Brawley, V.S. et al. (2013) Combinational targeting offsets antigen escape and enhances effector functions of adoptively transferred T cells in glioblastoma. Mol. Ther. 21, 2087-2101
40. Kakarla, S., Chow, K.K., Mata, M., Shaffer, D.R., Song, X.-T., Wu, M.F., Liu, H., Wang, L.L., Rowley, D.R., Pfizenmaier, K. et al. (2013) Antitumor effects of chimeric receptor engineered human T cells directed to tumor stroma. Mol. Ther. 21, 1611-1620
41. Bielamowicz, K., Fousek, K., Byrd, T., Brawley, V.S., Krebs, S., Chow, K.K., Yi, Z., Dotti, G., Gottschalk, S., Hegde, M. et al. (2015) Multispecific T cells for the treatment of high grade gliomas [2015 ASPHO Abstracts]. Pediatr. Blood Cancer 62, S21-S119
42. Wilkie, S., van Schalkwyk, M.C.I., Hobbs, S., Davies, D.M., van der Stegen, S.J.C., Pereira, A.C.P., Burbridge, S.E., Box, C., Eccles, S.A. and Maher, J. (2012) Dual targeting of ErbB2 and MUC1 in breast cancer using chimeric antigen receptors engineered to provide complementary signaling. J. Clin. Immunol. 32, 1059-1070
43. Grada, Z., Hegde, M., Byrd, T., Shaffer, D.R., Ghazi, A., Brawley, V.S., Corder, A., Schönfeld, K., Koch, J., Dotti, G. et al. (2013) Tancar: a novel bispecific chimeric antigen receptor for cancer immunotherapy. Mol. Ther. Nucleic Acids 2, e105
44. Hegde, M., Wakefield, A., Brawley, V.S., Grada, Z., Byrd, T.T., Chow, K.K., Krebs, S.S., Heslop, H.E., Gottschalk, S.M., Yvon, E. et al. (2014) Genetic modification of T cells with a novel bispecific chimeric antigen receptor to enhance the control of high-grade glioma (HGG). ASCO Meeting Abstr. 32, 10027
45. Lamers, C.H.J., Sleijfer, S., Vulto, A.G., Kruit, W.H.J., Kliffen, M., Debets, R., Gratama, J.W., Stoter, G. and Oosterwijk, E. (2006) Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience. J. Clin. Oncol. 24, e20-e22
46. Kloss, C.C., Condomines, M., Cartellieri, M., Bachmann, M. and Sadelain, M. (2012) Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered t cells. Nat. Biotechnol. 31, 71-75
47. Lanitis, E., Poussin, M., Klattenhoff, A.W., Song, D., Sandaltzopoulos, R., June, C.H. and Powell, D.J. (2013) Chimeric antigen receptor T cells with dissociated signaling domains exhibit focused antitumor activity with reduced potential for toxicity in vivo. Cancer Immunol. Res. 1, 43-53
48. Wu, C.-Y., Roybal, K.T., Puchner, E.M., Onuffer, J. and Lim, W.A. (2015) Remote control of therapeutic T cells through a small molecule-gated chimeric receptor. Science 350, aab4077